The ESC/EASD risk model was less accurate in prediction of 10-year CVD and all-cause mortality in patients with T2DM compared to SCORE and most notably to single assessment of NT-proBNP.

This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

This Mendelian randomization study provided first evidence that the relationship between BP and risk for new-onset AF is likely causal.

Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.

Effect of edoxaban versus warfarin on the primary efficacy endpoint and primary safety endpoint was similar in women and men. However, edoxaban reduced risk of several bleeding outcomes to a greater extend in women compared to men.

Higher consumption of green tea was associated with lower all-cause mortality in persons with a history of stroke and MI, whereas higher coffee consumption was associated with lower risk in those without history of CVD and in those with MI.

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

The ACC has published a statement with key clinical risk considerations that offers guidance on the incorporation of CV risk into vaccine allocation prioritizing decisions.

Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.